Aims Renal denervation (RDN) can reduce blood pressure (BP) and slow the decline of
renal function in chronic kidney disease (CKD) up to one year. Whether this effect is …

Objectives: Arterial hypertension and increased sympathetic activity are underlying
pathogenetic mechanisms of the progressive loss of renal function in patients with chronic …

Aims Several studies and registries have demonstrated sustained reductions in blood
pressure (BP) after renal denervation (RDN). The long-term safety and efficacy after RDN in …

Background Activity of the sympathetic nervous system is increased in patients with
hypertension and chronic kidney disease (CKD). Here we compare short-and long-term …

Background Sympathetic nerve activity is a hallmark of hypertension in end-stage renal
disease (ESRD). An initial proof-of-concept study implies that renal denervation (RDN) is …

530 Hypertension September 2018 patients who underwent RDN, had a reduction in office
BP (− 32/− 12 mm Hg) compared with baseline, whereas in the control group, BP did not …

Introduction Studies on the blood pressure lowering effect of renal denervation (RDN) in
resistant hypertensive patients have produced conflicting results. Change in medication …

Background Renal denervation (RDN) is a new treatment for hypertension in patients with
chronic kidney disease (CKD), but its efficacy is still debated. This meta-analysis aimed to …

We did a subject-level meta-analysis of the changes (Δ) in blood pressure (BP) observed 3
and 6 months after renal denervation (RDN) at 10 European centers. Recruited patients (n …

Background Renal denervation (RDN) reduces blood pressure (BP) in patients with
uncontrolled hypertension in the absence of antihypertensive medications. Objectives This …